



SUPPLEMENTAL FIGURE 1. Bland-Altman plots for tumor-to-liver ratios on single photon emission tomography (SPECT) as calculated by the two software systems (respectively Hermes and IRW). Bland-Altman analysis indicates the difference of the estimates obtained by the two methods in relation to the average of these estimates. The dotted lines represent the Bland-Altman limits ($\pm 1.96 \times \text{SD}$) and the solid line represents the mean difference and the dashed line is the line of equality.

SUPPLEMENTAL TABLE 1. Patient Characteristics

No.	Genotype	Age (yrs)	Sex (M/F)	Tumor location (A/EA)	Episode	Max. tumor diameter (cm)	Total plasma MN ¹	Type scanner ²	T/L ratio planar Hermes	T/L ratio SPECT Hermes	T/L ratio SPECT IRW	Daily dose potential interfering drug
1	Sporadic	49	F	RA	Primary	4,0	9972	Ecam Dual	1,53	4,78	4,87	
2	Sporadic	54	F	LA	Primary	6,0	36980	Ecam Dual	2,05	3,14	3,09	
3	Sporadic	49	F	LA	Primary	3,0	8050	Ecam Dual	1,28	10,40	10,83	Labetolol 600 mg
4	Sporadic	34	F	LA	Primary	3,5	3543	Ecam Dual	0,77	2,66	2,74	Nifedipine 60 mg
5	Sporadic	59	M	LA	Primary	11,0	136000	Ecam Dual	4,22	26,19	25,45	
6	Sporadic	66	M	RA	Primary	4,5	10255	Ecam Dual	1,47	6,44	6,28	
7	Sporadic	54	F	LA	Primary	11,0	21665	Symbia T16	1,43	3,97	3,61	
8	Sporadic	63	F	RA	Primary	3,5	5667	Symbia T16	1,44	3,41	3,43	Lercanidipine 10 mg
9	Sporadic	55	M	RA	Primary	2,0	1287	Ecam Dual	1,31	6,77	6,30	
10	Sporadic	39	F	RA	Primary	8,0	43687	Ecam Dual	1,34	1,72	1,77	
11	Sporadic	64	F	RA	Primary	14,0	229400	Ecam Dual	5,58	20,66	19,35	
12	Sporadic	52	M	EA	Primary	4,8	10633	Ecam Dual	0,85	9,79	9,79	Amlodipine 20 mg
13	Sporadic	29	M	EA	Primary	9,0	1207	Symbia T16	2,92	27,72	29,35	
14	Sporadic	55	F	LA	Primary	6,5	9945	Ecam Dual	NA	5,02	5,32	
15	Sporadic	51	M	EA	Metastasis	2,0	1173	Symbia T16	1,76	7,94	7,66	
15	Sporadic	49	M	RA	Primary	6,2	13479	Ecam Dual	1,79	7,31	7,47	
16	Sporadic	31	F	RA	Primary	5,0	17210	Ecam Dual	1,16	13,38	13,79	
17	Sporadic	70	F	RA	Primary	2,5	2007	Symbia T16	0,95	3,02	2,97	
18	Sporadic	69	F	EA	Metastasis	0,6	1489	Infinia	1,33	9,87	9,58	
19	Sporadic	34	F	RA	Primary	2,9	5171	Ecam Dual	0,15	0,86	0,71	
20	Sporadic	50	F	LA	Primary	4,9	16762	Symbia T16	1,18	3,83	3,72	Nifedipine 30 mg
21	Sporadic	39	F	RA	Primary	8,5	62121	Symbia T16	6,78	55,80	54,33	
22	Sporadic	41	F	RA	Primary	4,5	4211	Ecam Dual	3,49	11,43	11,12	Labetolol 200 mg
23	Sporadic	26	M	RA	Primary	4,3	1720	Ecam Dual	NA	1,46	1,39	
24	Sporadic	53	M	LA	Primary	5,5	25294	Symbia T16	0,49	1,00	1,00	
25	Sporadic	17	F	RA	Primary	3,5	7711	Symbia T16	3,04	1,57	1,77	
26	Sporadic	32	F	LA	Primary	4,0	3604	Symbia T16	NA	6,71	6,72	Amytriptiline 35 mg
27	Sporadic	30	M	RA	Primary	6,5	46660	Ecam Dual	3,43	13,24	12,35	
28	Sporadic	34	F	RA	Primary	4,5	14287	Symbia T16	1,53	6,58	7,04	
29	Sporadic	25	F	LA	Primary	2,3	3383	Ecam Dual	0,44	2,11	1,92	
30	Sporadic	63	M	LA	Primary	1,8	1061	Symbia T16	NA	1,98	1,98	Diltiazem 120 mg
31	Sporadic	35	F	LA	Primary	6,2	22599	Symbia T16	4,78	14,95	15,66	
32	Sporadic	16	F	RA	Primary	4,8	9896	Symbia T16	1,04	1,95	1,88	

33	Sporadic	43	F	LA	Primary	5,6	13750	Ecam Dual	1,24	4,10	3,10	
34	MEN-2	36	M	LA	Primary	5,0	1372	Ecam Dual	0,61	6,00	5,56	
35	MEN-2	29	F	LA	Primary	2,5	8082	Symbia T16	1,37	8,66	8,48	
36	MEN-2	36	M	LA	Primary	,9	1480	Ecam Dual	0,90	5,22	5,08	
37	MEN-2	56	M	LA	Primary	1,4	833	Ecam Dual	0,53	2,78	3,08	
38	MEN-2	44	M	RA	Primary	2,5	2339	Ecam Dual	1,23	5,87	5,42	
39	MEN-2	35	F	LA	Primary	2,5	4142	Ecam Dual	1,04	5,06	4,59	
40	MEN-2	58	F	LA	Primary	1,0	1928	Ecam Dual	1,08	2,25	2,10	Amlodipine 5 mg
41	MEN-2	50	M	LA	Primary	3,2	1837	Symbia T16	0,99	11,19	11,09	
42	MEN-2	55	M	LA	Primary	2,3	NA	Ecam Dual	0,66	2,72	2,68	
43	MEN-2	71	M	RA	Primary	3,5	2379	Ecam Dual	1,14	3,40	3,50	
44	MEN-2 ³	61	M	LA	Primary	5,0	13804	Ecam Dual	2,31	7,90	7,17	
44	MEN-2 ³	61	M	RA	Primary	8,0	13804	Ecam Dual	1,06	8,62	9,73	
45	MEN-2 ³	47	F	LA	Primary	8,0	25908	Symbia T16	1,53	5,83	5,83	
45	MEN-2 ³	47	F	RA	Primary	6,5	25908	Symbia T16	1,66	5,40	5,40	
46	MAX	57	M	LA	Primary	1,8	2904	Ecam Dual	0,64	4,99	5,27	
47	NF1	37	F	EA	Primary	3,6	7752	Ecam Dual	1,42	9,08	9,45	
48	NF1	59	F	LA	Primary	7,0	27931	Ecam Dual	2,17	6,18	6,00	Formoterol(dose NA)
49	SDHA	19	F	RA	Primary	8,0	5164	Ecam Dual	2,71	6,44	6,36	
50	SDHB ²	46	M	EA	Metastasis	6,4	728	Symbia T16	0,56	6,48	7,00	
51	SDHB	14	F	EA	Primary	5,0	27676	Symbia T16	3,81	12,83	12,48	
52	SDHD ⁴	32	M	EA	Primary	3,0	2173	Ecam Dual	1,04	8,56	8,45	
52	SDHD ⁴	32	M	EA	Primary	2,5	2173	Ecam Dual	0,55	5,43	5,28	
53	SDHD	34	F	EA	Primary	2,5	2782	Symbia T16	0,86	4,87	4,91	
54	SDHD	59	F	EA	Primary	5,2	907	Ecam Dual	4,45	40,94	39,36	
55	SDHD	65	M	LA	Primary	4,0	6448	Symbia T16	1,24	5,05	5,32	Amlodipine 5 mg
56	VHL ⁵	32	M	EA	Primary	2,5	1245	Ecam Dual	0,96	2,72	2,83	
56	VHL ⁵	32	M	RA	Primary	1,5	1245	Ecam Dual	0,34	3,36	2,12	
57	VHL ²	8	F	EA	Metastasis	2,7	27452	Ecam Dual	2,23	6,86	6,64	

In total 57 patients.

¹Upper reference limit of plasma metanephrines is 106-940 pmol/L.

²All Siemens except one patient (GE Healthcare Infinia).

Abbreviations: M=male, F=female, yrs=years, A=adrenal, EA=extra-adrenal, MN=metanephrines,

NA=not assessed.